Refinement of prognostication for IDH ‐mutant astrocytomas using DNA methylation‐based classification
Brain Pathology · 2024
DOI: 10.1111/bpa.13233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Pathology, 2024. Verfasst von Teresia Kling und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sahlgrenska Center for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, Universit…. Hauptthemen laut MEDLINE: Astrocytoma, DNA Methylation, Isocitrate Dehydrogenase, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Swedish state under the agreement between the Swedish government and the county councils - the ALF-agreement, Vetenskapsrådet, Cancerfonden.
Abstract (Originalsprache)
The 2021 World Health Organization (WHO) grading system of isocitrate dehydrogenase ( IDH )‐mutant astrocytomas relies on histological features and the presence of homozygous deletion of the cyclin‐dependent kinase inhibitor 2A and 2B ( CDKN2A/B ). DNA methylation profiling has become highly relevant in the diagnosis of central nervous system (CNS) tumors including gliomas, and it has been incorporated into routine clinical diagnostics in some countries. In this study, we, therefore, examined the value of DNA methylation‐based classification for prognostication of patients with IDH ‐mutant astrocytomas. We analyzed histopathological diagnoses, genome‐wide DNA methylation array data, and chromosomal copy number alteration profiles from a cohort of 385 adult‐type IDH ‐mutant astrocytomas, including a local cohort of 127 cases and 258 cases from public repositories. Prognosis based on WHO 2021 CNS criteria (histological grade and CDKN2A/B homozygous deletion status), other relevant chromosomal/gene alterations in IDH ‐mutant astrocytomas and DNA methylation‐based subclassification according to the molecular neuropathology classifier were assessed. We demonstrate that DNA methylation‐based classification of IDH ‐mutant astrocytomas can be used to predict outcome of the patients equally well as WHO 2021 CNS criteria. In addition, methylation‐based subclassification enabled the identification of IDH ‐mutant astrocytoma patients with poor survival among patients with grade 3 tumors and patients with grade 4 tumors with a more favorable outcome. In conclusion, DNA methylation‐based subclassification adds prognostic information for IDH ‐mutant astrocytomas that can further refine the current WHO 2021 grading scheme for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sahlgrenska Center for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
ORCID-Profile: Helena Carén
Förderung
- The Swedish state under the agreement between the Swedish government and the county councils - the ALF-agreement
- Vetenskapsrådet
- Cancerfonden
- Swedish Research Council
Zitieren
APA
Kling, T., Ferreyra Vega, S., Suman, M., Dénes, A., Lipatnikova, A., Lagerström, S., Olsson Bontell, T., Jakola, A. S., & Carén, H. (2024). Refinement of prognostication for IDH ‐mutant astrocytomas using DNA methylation‐based classification. Brain Pathology. https://doi.org/10.1111/bpa.13233
Vancouver
Kling T, Ferreyra Vega S, Suman M, Dénes A, Lipatnikova A, Lagerström S, et al. Refinement of prognostication for IDH ‐mutant astrocytomas using DNA methylation‐based classification. Brain Pathology. 2024. doi:10.1111/bpa.13233
BibTeX
@article{Kling2024,
author = {Kling, Teresia and Ferreyra Vega, Sandra and Suman, Medha and Dénes, Anna and Lipatnikova, Anna and Lagerström, Stina and Olsson Bontell, Thomas and Jakola, Asgeir Store and Carén, Helena},
title = {Refinement of prognostication for IDH ‐mutant astrocytomas using DNA methylation‐based classification},
journal = {Brain Pathology},
year = {2024},
doi = {10.1111/bpa.13233}
}
EUVIMED